[HTML][HTML] c-Myc-XRCC2-FOS axis promotes the proliferation and the resistance to Doxorubicin of NSCLC
P Zhang, H Li, H Gong, Y Tian, F Chen, X Li… - Biomedicine & …, 2024 - Elsevier
Lung cancer represents one of the most prevalent malignant neoplasms, commanding an
alarming incidence and mortality rate globally. Non-small cell lung cancer (NSCLC) …
alarming incidence and mortality rate globally. Non-small cell lung cancer (NSCLC) …
[HTML][HTML] Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors—a …
L Guo, J Li, J Wang, X Chen, C Cai… - Translational Lung …, 2024 - pmc.ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) have become one of the standard
treatments for non-small cell lung cancer (NSCLC) patients without driver mutations …
treatments for non-small cell lung cancer (NSCLC) patients without driver mutations …